Yes, thank you.
I can address that question, as it relates to Canada as well as to some other jurisdictions. To my knowledge, Roche stopped manufacturing, or distributing, or marketing its brand, Lariam, some time in the past few years. It was this decade, anyway. This is coincident with a trend of Lariam being discontinued in a number of other markets. Roche discontinued the sale of Lariam in the United States, I believe, in 2009. It recently discontinued the sale of the drug in Ireland and in a number of other European countries.
It is decidedly unusual for a drug company to discontinue the sale of a drug that has such good name recognition. The marketing value of the brand name typically means that the drug will remain profitable, even up against possibly lower-priced generics. There's widespread speculation that the decision by Roche to cease the marketing of Lariam in the United States, Canada, and other jurisdictions was arrived at for legal reasons, for concerns of legal exposure due to a potential for lawsuits related to the drug's use.
The company claims that it was a commercial decision based on declining sales. That's certainly the case. In the United States, generic mefloquine remains available—and it is available for sale independently of concerns about legal liability. By a Supreme Court decision, generic drug manufacturers in the United States cannot be sued for deficits in the product labelling or for a failure to warn. I don't know enough about the legal systems in other jurisdictions, including Canada, to know if similar motivation informs the continued sale of mefloquine here.
I hope that addresses your question.